BioSpace News Archive

Berkeley-based precision medicine solutions provider Newomics Inc. has announced the commercial placement of its 100th mass spectrometry front-end system, which has contributed to successful customer applications in the development of biotherapeutics such as Covid-19 antibodies and gene therapy, blood-based clinical diagnosis, and proteomics research.

PetDx® – The Liquid Biopsy Company for Pets™ published a study describing the optimal age to begin cancer screening for dogs in PLOS ONE, a peer-reviewed open-access scientific journal from the Public Library of Science.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on February 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 7 individuals hired by Acutus in January 2023.

Sensus Healthcare, Inc. announces that management will hold a conference call on Thursday, February 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2022.

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit technology platform, today announced that Tim Lu, MD, PhD, Senti’s Co-Founder and CEO, will present at the SVB Securities Global Biopharma Conference.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced that the company will release financial results for the fourth quarter and year-end 2022, after the market close on Wednesday, February 8, 2023.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 113,250 restricted stock units to ten newly-hired employees.

Roivant Sciences Ltd. announced that it has commenced an underwritten public offering of $150 million of common shares.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 18,000 shares of Akebia’s common stock on January 31, 2023, as inducements material to such employee entering into employment with Akebia.